Imagion Biosystems Ltd
ASX:IBX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Imagion Biosystems Ltd
Net Income (Common)
Imagion Biosystems Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Imagion Biosystems Ltd
ASX:IBX
|
Net Income (Common)
-AU$4.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Net Income (Common)
-AU$2.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Cochlear Ltd
ASX:COH
|
Net Income (Common)
AU$345.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Net Income (Common)
-AU$7.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-19%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Net Income (Common)
AU$7.8m
|
CAGR 3-Years
52%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Net Income (Common)
-AU$10.2m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Imagion Biosystems Ltd
Glance View
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The firm's principal activities include nanotechnology, biotechnology, cancer diagnostics and medical imaging using superparamagnetic relaxometry. Its MagSense technology is a functional imaging method for detecting cancers and other critical diseases. MagSense instrument uses sensitive magnetic sensors to detect the tiny bio-safe nanoparticles. MagSense nanoparticles bound to cancer cells act like a magnetic beacon to identify the presence of a tumour. MagSense nanoparticles are supplied as an injectable solution and formulated to provide delivery to specific types of cancer cells. Its PrecisionMRX nanoparticles are developed for magnetic relaxometry and other biomedical applications. The company serves a range of applications, including detecting cancer, monitoring therapy and detecting other diseases. Its MagSense HER2 imaging agent is under phase I clinical study.
See Also
What is Imagion Biosystems Ltd's Net Income (Common)?
Net Income (Common)
-4.3m
AUD
Based on the financial report for Dec 31, 2025, Imagion Biosystems Ltd's Net Income (Common) amounts to -4.3m AUD.
What is Imagion Biosystems Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
4%
Over the last year, the Net Income (Common) growth was -108%. The average annual Net Income (Common) growth rates for Imagion Biosystems Ltd have been 24% over the past three years , 4% over the past five years .
